Potential role of 5-Aza-2′-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer

Surgery (United States)

Volumn 154, Issue 6, 2013, Pages 1456-1462

  Gunda, Viswanath ^a   Cogdill, Alexandria P ^a   Bernasconi, Maria J ^a   Wargo, Jennifer A ^a   Parangi, Sareh ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MELANOMA ANTIGEN 4; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA CELL; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID NEOPLASMS;

EID: 84887959659     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.07.009     Document Type: Article

References (25)

1. C. Nucera, M.A. Nehs, M. Mekel, X. Zhang, R. Hodin, and J. Lawler A novel orthotopic mouse model of human anaplastic thyroid carcinoma Thyroid 19 2009 1077 1084
2. M. Xing BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocrine Rev 28 2007 742 762
3. C. Nucera, M.A. Nehs, S.S. Nagarkatti, P.M. Sadow, M. Mekel, and A.H. Fischer Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer Oncologist 16 2011 296 309
4. C.U. Blank, A.I. Hooijkaas, J.B. Haanen, and T.N. Schumacher Combination of targeted therapy and immunotherapy in melanoma Cancer Immunol Immunother 60 2011 1359 1371
5. J.S. Wilmott, G.V. Long, J.R. Howle, L.E. Haydu, R.N. Sharma, and J.F. Thompson Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma Clin Cancer Res 18 2012 1386 1394
6. A. Boni, A.P. Cogdill, P. Dang, D. Udayakumar, C.N. Njauw, and C.M. Sloss Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res 70 2010 5213 5219
7. M. Sang, Y. Lian, X. Zhou, and B. Shan MAGE-A family: attractive targets for cancer immunotherapy Vaccine 29 2011 8496 8500
8. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat Med 10 2004 909 915
9. M.T. Duffour, P. Chaux, C. Lurquin, G. Cornelis, T. Boon, and P. van der Bruggen A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes Eur J Immunol 29 1999 3329 3337
10. M.A. Morse, J. Garst, T. Osada, S. Khan, A. Hobeika, and T.M. Clay A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer J Transl Med 3 2005 9
11. O.L. Caballero, and Y.T. Chen Cancer/testis (CT) antigens: potential targets for immunotherapy Cancer Sci 100 2009 2014 2021
12. Z.C. Jia, B. Ni, Z.M. Huang, Y. Tian, J. Tang, and J.X. Wang Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4 Clin Dev Immunol 2010 2010 567594
13. Z.Y. Wu, Y.F. Gao, Y.H. Wu, W. Liu, M. Sun, and M.X. Zhai Identification of a novel CD8+ T cell epitope derived from cancer-testis antigen MAGE-4 in oesophageal carcinoma Scand J Immunol 74 2011 561 567
14. N. Takahashi, T. Ohkuri, S. Homma, J. Ohtake, D. Wakita, and Y. Togashi First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen Cancer Sci 103 2012 150 153
15. L. Sigalotti, S. Coral, G. Nardi, A. Spessotto, E. Cortini, and I. Cattarossi Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma J Immunother 25 2002 16 26
16. S.J. Adair, and K.T. Hogan Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules Cancer Immunol Immunother 58 2009 589 601
17. S. Coral, L. Sigalotti, M. Altomonte, A. Engelsberg, F. Colizzi, and I. Cattarossi 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications Clinical Cancer Res 8 2002 2690 2695
18. M. Milkovic, B. Sarcevic, and E. Glavan Expression of MAGE tumor-associated antigen in thyroid carcinomas Endocrine Pathol 17 2006 45 52
19. I. Ruschenburg, A. Kubitz, T. Schlott, M. Korabiowska, and M. Droese MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter Int J Mol Med 4 1999 445 448
20. M. Bolli, E. Schultz-Thater, P. Zajac, U. Guller, C. Feder, and F. Sanguedolce NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study Int J Cancer 115 2005 960 966
21. D.H. Melo, R.C. Mamede, L. Neder, F.P. Saggioro, D.L. Figueiredo, and W.A. da Silva Jr. Expression of MAGE-A4 and MAGE-C1 tumor-associated antigen in benign and malignant thyroid diseases Head Neck 33 2011 1426 1432
22. A. Ribas, and K.T. Flaherty BRAF targeted therapy changes the treatment paradigm in melanoma Nat Rev Clin Oncol 8 2011 426 433
23. G. Qiu, J. Fang, and Y. He 5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC Clin Biochem 39 2006 259 266
24. C. Nucera, M. Goldfarb, R. Hodin, and S. Parangi Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E) Biochim Biophys Acta 1795 2009 152 161
25. E. De Plaen, B. Naerhuyzen, C. De Smet, J.P. Szikora, and T. Boon Alternative promoters of gene MAGE4a Genomics 40 1997 305 313